hydroxyurea has been researched along with Asthma in 86 studies
Asthma: A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).
Excerpt | Relevance | Reference |
---|---|---|
"In a non-randomized, non-placebo, single-blind, fixed sequence, pilot study, we evaluated 22 non-smoking, stable, moderate-severe adult asthmatics on maintenance inhaled fluticasone 250 microg/salmeterol 50 microg (F/S) via MDI bid> or =1 yr, with add-on oral zileuton 600 mg qid." | 9.14 | Role of add-on zileuton on total exhaled, large airway, and small airway/alveolar nitric oxide in moderate-severe persistent adult asthmatics on fluticasone 250 microg/Salmeterol 50 microg. ( Gelb, AF; Shinar, C; Simmons, M; Taylor, CF, 2009) |
"To assess the therapeutic effects of oral zileuton tablets combined with low-dose beclomethasone compared to doubling the dose of beclomethasone, in improving lung function and reducing asthma symptoms." | 9.12 | Zileuton added to low-dose inhaled beclomethasone for the treatment of moderate to severe persistent asthma. ( Balter, M; Boulet, LP; Cairns, CB; Löfdahl, CG; O'Connor, BJ; Szczeklik, A, 2007) |
"This study was conducted to assess the safety and efficacy of zileuton controlled release [CR] 1,200 mg BID added to usual care (UC) in 926 patients with moderate asthma (619 patients randomized to zileuton CR and 307 to placebo)." | 9.12 | The safety and efficacy of zileuton controlled-release tablets as adjunctive therapy to usual care in the treatment of moderate persistent asthma: a 6-month randomized controlled study. ( Busse, W; Calhoun, W; Dube, L; Harris, J; Panettieri, R; Peters-Golden, M; Russell, H; Walton-Bowen, K; Wenzel, S, 2007) |
"Patients with moderate asthma treated with short-acting beta-agonists only were randomized to receive zileuton CR, 1,200 mg twice daily (n = 206); placebo CR, twice daily (n = 203); zileuton immediate-release (IR), 600 mg 4 times daily (n = 101); or placebo IR, 4 times daily (n = 103), for 12 weeks." | 9.12 | Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: a 3-month randomized controlled study. ( Berger, W; Casale, T; Corren, J; Dube, L; Kemp, J; LaVallee, N; Nelson, H; Stepanians, M; Walton-Bowen, K, 2007) |
"Zileuton is a 5-lipoxygenase inhibitor approved by the US FDA in 1996 for the treatment of asthma in adults and children." | 9.12 | Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma. ( Cameron, CM; Dube, LM; Kasten, LE; Walton-Bowen, K; Watkins, PB, 2007) |
" Since Zileuton, also an inhibitor of 5-LOX, attenuates asthma but with an undesirable side effect, we investigated whether dietary GLA would suppress biosynthesis of PMN-LTB4 isolated from asthma patients and attenuate asthma." | 9.11 | Suppression of leukotriene B4 generation by ex-vivo neutrophils isolated from asthma patients on dietary supplementation with gammalinolenic acid-containing borage oil: possible implication in asthma. ( Gershwin, ME; Morrissey, BM; Naguwa, S; Vang, K; Watnik, M; Wineinger, J; Ziboh, VA, 2004) |
"The objective of this study was to determine the effects of allergen exposure on leukotriene generation and inflammation within the airways of allergic asthmatics and evaluate the effects of the 5-lipoxygenase inhibitor zileuton on these responses." | 9.09 | Anti-inflammatory effects of zileuton in a subpopulation of allergic asthmatics. ( Bleecker, ER; Dubé, LM; Hasday, JD; Hebel, JR; Lanni, C; Meltzer, SS; Moore, WC; Wisniewski, P, 2000) |
"From bronchoprovocation studies and investigations of the acute effects of drugs that inhibit leukotrienes (LT), the hypothesis has emerged that leukotrienes are important mediators of airway obstruction and other symptoms in aspirin-intolerant asthma (AIA)." | 9.08 | Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. ( Bochenek, G; Boodhoo, TI; Dahlén, B; Dahlén, SE; Dubé, LM; Kumlin, M; Mastalerz, L; Nizankowska, E; Pinis, G; Swanson, LJ; Szczeklik, A; Wright, S; Zetterström, O, 1998) |
"Zileuton, a leukotriene pathway inhibitor used to treat asthma, improves lung function, relieves symptoms, and is well tolerated." | 9.08 | Safety and clinical efficacy of zileuton in patients with chronic asthma. ( Carpentier, PJ; Dubé, LM; Kemp, JP; Lancaster, JF; Lazarus, SC; Lee, T; Ochs, RF; Wenzel, S, 1998) |
"The aim of the study was to determine whether zileuton, an inhibitor of 5-lipoxygenase, attenuated bronchial hyperresponsiveness (BHR) in asthmatic subjects who had marked BHR during maintenance treatment with inhaled corticosteroids (ICS)." | 9.08 | Effects of single-dose zileuton on bronchial hyperresponsiveness in asthmatic patients treated with inhaled corticosteroids. ( Bootsma, GP; Dekhuijzen, PN; Festen, J; van den Berg, LR; van Herwaarden, CL; Wielders, PL, 1997) |
"Zileuton, a leukotriene pathway inhibitor, was compared with slowly absorbed theophylline in a randomized, double-blind study of patients with chronic asthma." | 9.08 | A randomized controlled trial comparing zileuton with theophylline in moderate asthma. The Zileuton Study Group. ( Dubé, LM; Lancaster, JF; Petty, T; Schwartz, HJ; Swanson, LJ, 1998) |
" In the present study we examined the effect of oral ABT-761, a novel 5-lipoxygenase (5-LO) inhibitor, on exercise- and adenosine (AMP)-induced bronchoconstriction in nine asthmatics." | 9.08 | The effect of ABT-761, a novel 5-lipoxygenase inhibitor, on exercise- and adenosine-induced bronchoconstriction in asthmatic subjects. ( Carpentier, PJ; Drajesk, JF; Joos, GF; Kips, JC; Pauwels, RA; Van Schoor, J, 1997) |
"Zileuton produces objective and subjective improvements in patients with mild to moderate asthma and is well tolerated." | 9.08 | Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group. ( Dubé, LM; Lancaster, J; Liu, MC, 1996) |
"1%) of 132 patients receiving 600 mg of zileuton four times a day required corticosteroid treatment for asthma vs 21 (15." | 9.08 | Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. ( Cohn, J; Drazen, JM; Dubé, L; Israel, E, 1996) |
"To evaluate the effectiveness of inhibiting the formation of the 5-lipoxygenase products of arachidonic acid by the 5-lipoxygenase inhibitor zileuton in the treatment of mild-to-moderate asthma." | 9.07 | The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. ( Busse, W; Cohn, J; Drazen, JM; Fish, J; Grossman, J; Israel, E; Kaiser, HB; Karahalios, P; Kemp, JP; Lanni, C; Ledford, D; Murray, JJ; Pearlman, H; Pierson, W; Rosenthal, R; Rubin, P; Segal, AT; Siegel, SC; Tinkelman, D; Wenzel, S, 1993) |
"The increase in nasal symptoms in aspirin-sensitive patients with asthma after aspirin ingestion is associated with increases in nasal tryptase, histamine, and cysteinyl leukotriene levels." | 9.07 | Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. ( Callery, JC; Cohn, J; Drazen, JM; Fischer, AR; Igarashi, Y; Kaliner, MA; Lilly, CM; Rosenberg, MA; Rubin, P; White, MV, 1994) |
"A subset of persons with asthma develop bronchospasm, naso-ocular, gastrointestinal, and/or dermal reactions after ingesting aspirin (ASA) or agents with the capacity to inhibit cyclooxygenase." | 9.07 | The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. ( Callery, JC; Cohn, J; Drazen, JM; Fischer, AR; Israel, E; Lilly, CM; Rosenberg, MA; Rubin, P; Shapiro, J, 1993) |
"We sought to study our hypothesis that response to zileuton varies across specific asthmatic phenotypes." | 7.96 | Zileuton use and phenotypic features in asthma. ( Holguin, F; Nouraie, M; Parikh, A; Thalanayar Muthukrishnan, P, 2020) |
"Variable responsiveness to zileuton, a leukotriene antagonist used to treat asthma, may be due in part to genetic variation." | 7.88 | The phosphatidylinositide 3-kinase (PI3K) signaling pathway is a determinant of zileuton response in adults with asthma. ( Dahlin, A; Irvin, CG; Kubo, M; Lima, JJ; Litonjua, AA; Peters, SP; Qiu, W; Tamari, M; Tantisira, KG; Weiss, ST; Wu, AC, 2018) |
"Leukotriene B4 (LTB4), a potent chemokinetic mediator for neutrophils, is enhanced by interleukin-8 (IL-8) and may play a key role in the inflammatory response of asthma." | 7.70 | Allergen-stimulated leukotriene B4 and interleukin-8 levels in patients with asthma and allergic rhinitis-modulation by a lipid pathway inhibitor. ( Bouboulis, D; Frieri, M; Lark, G; Sansone, G; Schaefer, PA; Therattil, JM; Wang, SF; Zitt, M, 1998) |
" Patients who demonstrate improved asthma control with zileuton 600 mg QID may be able to reduce their daily dosage and/or frequency while still maintaining the same level of symptom control." | 6.68 | Randomized trial of zileuton in patients with moderate asthma: effect of reduced dosing frequency and amounts on pulmonary function and asthma symptoms. Zileuton Study Group. ( Dubé, LM; DuBuske, LM; Grossman, J; Lancaster, JF; Swanson, LJ, 1997) |
"Treatment with Zileuton for 2 weeks significantly increased thromboxane B(2) levels from baseline levels of 267 +/- 54 microg/l to 389 +/- 62 microg/l after 2 weeks of treatment (P < 0." | 5.32 | Zileuton, a 5-lipoxygenase inhibitor, increases production of thromboxane A2 and platelet aggregation in patients with asthma. ( Dev, A; Leong, AB; Wu, X, 2003) |
"Aspirin sensitivity was established previously in all six patients during a prior ASA oral challenge." | 5.31 | Lack of effect of the 5-lipoxygenase inhibitor zileuton in blocking oral aspirin challenges in aspirin-sensitive asthmatics. ( Daffern, PJ; Pauls, JD; Simon, RA; Stevenson, DD, 2000) |
"In a non-randomized, non-placebo, single-blind, fixed sequence, pilot study, we evaluated 22 non-smoking, stable, moderate-severe adult asthmatics on maintenance inhaled fluticasone 250 microg/salmeterol 50 microg (F/S) via MDI bid> or =1 yr, with add-on oral zileuton 600 mg qid." | 5.14 | Role of add-on zileuton on total exhaled, large airway, and small airway/alveolar nitric oxide in moderate-severe persistent adult asthmatics on fluticasone 250 microg/Salmeterol 50 microg. ( Gelb, AF; Shinar, C; Simmons, M; Taylor, CF, 2009) |
"To assess the therapeutic effects of oral zileuton tablets combined with low-dose beclomethasone compared to doubling the dose of beclomethasone, in improving lung function and reducing asthma symptoms." | 5.12 | Zileuton added to low-dose inhaled beclomethasone for the treatment of moderate to severe persistent asthma. ( Balter, M; Boulet, LP; Cairns, CB; Löfdahl, CG; O'Connor, BJ; Szczeklik, A, 2007) |
"To evaluate whether controller medications, particularly leukotriene modifier drugs, taken during oral aspirin challenges can reduce the risk of severe asthmatic responses." | 5.12 | Effect of leukotriene modifier drugs on the safety of oral aspirin challenges. ( Ludington, E; Mehra, P; Simon, RA; Stevenson, DD; White, A, 2006) |
"This study was conducted to assess the safety and efficacy of zileuton controlled release [CR] 1,200 mg BID added to usual care (UC) in 926 patients with moderate asthma (619 patients randomized to zileuton CR and 307 to placebo)." | 5.12 | The safety and efficacy of zileuton controlled-release tablets as adjunctive therapy to usual care in the treatment of moderate persistent asthma: a 6-month randomized controlled study. ( Busse, W; Calhoun, W; Dube, L; Harris, J; Panettieri, R; Peters-Golden, M; Russell, H; Walton-Bowen, K; Wenzel, S, 2007) |
"Patients with moderate asthma treated with short-acting beta-agonists only were randomized to receive zileuton CR, 1,200 mg twice daily (n = 206); placebo CR, twice daily (n = 203); zileuton immediate-release (IR), 600 mg 4 times daily (n = 101); or placebo IR, 4 times daily (n = 103), for 12 weeks." | 5.12 | Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: a 3-month randomized controlled study. ( Berger, W; Casale, T; Corren, J; Dube, L; Kemp, J; LaVallee, N; Nelson, H; Stepanians, M; Walton-Bowen, K, 2007) |
"Zileuton is a 5-lipoxygenase inhibitor approved by the US FDA in 1996 for the treatment of asthma in adults and children." | 5.12 | Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma. ( Cameron, CM; Dube, LM; Kasten, LE; Walton-Bowen, K; Watkins, PB, 2007) |
" Since Zileuton, also an inhibitor of 5-LOX, attenuates asthma but with an undesirable side effect, we investigated whether dietary GLA would suppress biosynthesis of PMN-LTB4 isolated from asthma patients and attenuate asthma." | 5.11 | Suppression of leukotriene B4 generation by ex-vivo neutrophils isolated from asthma patients on dietary supplementation with gammalinolenic acid-containing borage oil: possible implication in asthma. ( Gershwin, ME; Morrissey, BM; Naguwa, S; Vang, K; Watnik, M; Wineinger, J; Ziboh, VA, 2004) |
"The objective of this study was to determine the effects of allergen exposure on leukotriene generation and inflammation within the airways of allergic asthmatics and evaluate the effects of the 5-lipoxygenase inhibitor zileuton on these responses." | 5.09 | Anti-inflammatory effects of zileuton in a subpopulation of allergic asthmatics. ( Bleecker, ER; Dubé, LM; Hasday, JD; Hebel, JR; Lanni, C; Meltzer, SS; Moore, WC; Wisniewski, P, 2000) |
"Zileuton, a leukotriene pathway inhibitor, was compared with slowly absorbed theophylline in a randomized, double-blind study of patients with chronic asthma." | 5.08 | A randomized controlled trial comparing zileuton with theophylline in moderate asthma. The Zileuton Study Group. ( Dubé, LM; Lancaster, JF; Petty, T; Schwartz, HJ; Swanson, LJ, 1998) |
"The aim of the study was to determine whether zileuton, an inhibitor of 5-lipoxygenase, attenuated bronchial hyperresponsiveness (BHR) in asthmatic subjects who had marked BHR during maintenance treatment with inhaled corticosteroids (ICS)." | 5.08 | Effects of single-dose zileuton on bronchial hyperresponsiveness in asthmatic patients treated with inhaled corticosteroids. ( Bootsma, GP; Dekhuijzen, PN; Festen, J; van den Berg, LR; van Herwaarden, CL; Wielders, PL, 1997) |
"From bronchoprovocation studies and investigations of the acute effects of drugs that inhibit leukotrienes (LT), the hypothesis has emerged that leukotrienes are important mediators of airway obstruction and other symptoms in aspirin-intolerant asthma (AIA)." | 5.08 | Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. ( Bochenek, G; Boodhoo, TI; Dahlén, B; Dahlén, SE; Dubé, LM; Kumlin, M; Mastalerz, L; Nizankowska, E; Pinis, G; Swanson, LJ; Szczeklik, A; Wright, S; Zetterström, O, 1998) |
" We investigated the effects of zileuton, an inhibitor of 5-lipoxygenase (5-LO), on airway responsiveness to cold, dry air in patients with moderate asthma." | 5.08 | Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects. ( Awni, WM; Cohn, J; Drazen, JM; Fischer, AR; Frantz, R; Israel, E; McFadden, CA, 1995) |
"Zileuton, a leukotriene pathway inhibitor used to treat asthma, improves lung function, relieves symptoms, and is well tolerated." | 5.08 | Safety and clinical efficacy of zileuton in patients with chronic asthma. ( Carpentier, PJ; Dubé, LM; Kemp, JP; Lancaster, JF; Lazarus, SC; Lee, T; Ochs, RF; Wenzel, S, 1998) |
" In the present study we examined the effect of oral ABT-761, a novel 5-lipoxygenase (5-LO) inhibitor, on exercise- and adenosine (AMP)-induced bronchoconstriction in nine asthmatics." | 5.08 | The effect of ABT-761, a novel 5-lipoxygenase inhibitor, on exercise- and adenosine-induced bronchoconstriction in asthmatic subjects. ( Carpentier, PJ; Drajesk, JF; Joos, GF; Kips, JC; Pauwels, RA; Van Schoor, J, 1997) |
"1%) of 132 patients receiving 600 mg of zileuton four times a day required corticosteroid treatment for asthma vs 21 (15." | 5.08 | Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. ( Cohn, J; Drazen, JM; Dubé, L; Israel, E, 1996) |
"Zileuton produces objective and subjective improvements in patients with mild to moderate asthma and is well tolerated." | 5.08 | Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group. ( Dubé, LM; Lancaster, J; Liu, MC, 1996) |
"To evaluate the effectiveness of inhibiting the formation of the 5-lipoxygenase products of arachidonic acid by the 5-lipoxygenase inhibitor zileuton in the treatment of mild-to-moderate asthma." | 5.07 | The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. ( Busse, W; Cohn, J; Drazen, JM; Fish, J; Grossman, J; Israel, E; Kaiser, HB; Karahalios, P; Kemp, JP; Lanni, C; Ledford, D; Murray, JJ; Pearlman, H; Pierson, W; Rosenthal, R; Rubin, P; Segal, AT; Siegel, SC; Tinkelman, D; Wenzel, S, 1993) |
"A subset of persons with asthma develop bronchospasm, naso-ocular, gastrointestinal, and/or dermal reactions after ingesting aspirin (ASA) or agents with the capacity to inhibit cyclooxygenase." | 5.07 | The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. ( Callery, JC; Cohn, J; Drazen, JM; Fischer, AR; Israel, E; Lilly, CM; Rosenberg, MA; Rubin, P; Shapiro, J, 1993) |
"The increase in nasal symptoms in aspirin-sensitive patients with asthma after aspirin ingestion is associated with increases in nasal tryptase, histamine, and cysteinyl leukotriene levels." | 5.07 | Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. ( Callery, JC; Cohn, J; Drazen, JM; Fischer, AR; Igarashi, Y; Kaliner, MA; Lilly, CM; Rosenberg, MA; Rubin, P; White, MV, 1994) |
"The effect of a single oral dose (800 mg) of zileuton (A-64077), a specific 5-lipoxygenase inhibitor, on the early and late airway responses to inhaled allergen was studied in a randomised, double blind, placebo controlled, and crossover trial in nine subjects with atopic asthma." | 5.07 | Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. ( Barnes, NC; Barnes, PJ; Hui, KP; Kesterson, J; Rubin, P; Taylor, GW; Taylor, IK, 1991) |
"The three leukotriene (LT) modifiers approved for use in the United States, zileuton, zafirlukast, and montelukast, are the first new class of therapeutic agents to be introduced in 20 years for the treatment of asthma." | 4.80 | New treatments for asthma: the role of leukotriene modifier agents. ( Valacer, DJ, 1999) |
"We sought to study our hypothesis that response to zileuton varies across specific asthmatic phenotypes." | 3.96 | Zileuton use and phenotypic features in asthma. ( Holguin, F; Nouraie, M; Parikh, A; Thalanayar Muthukrishnan, P, 2020) |
"Variable responsiveness to zileuton, a leukotriene antagonist used to treat asthma, may be due in part to genetic variation." | 3.88 | The phosphatidylinositide 3-kinase (PI3K) signaling pathway is a determinant of zileuton response in adults with asthma. ( Dahlin, A; Irvin, CG; Kubo, M; Lima, JJ; Litonjua, AA; Peters, SP; Qiu, W; Tamari, M; Tantisira, KG; Weiss, ST; Wu, AC, 2018) |
"This article presents information on the safety of zafirlukast, montelukast, and zileuton, three antileukotrienes (anti-LTs) approved in the United States for the prophylaxis and treatment of asthma." | 3.71 | Safety of antileukotriene agents in asthma management. ( Spector, SL, 2001) |
"Leukotriene B4 (LTB4), a potent chemokinetic mediator for neutrophils, is enhanced by interleukin-8 (IL-8) and may play a key role in the inflammatory response of asthma." | 3.70 | Allergen-stimulated leukotriene B4 and interleukin-8 levels in patients with asthma and allergic rhinitis-modulation by a lipid pathway inhibitor. ( Bouboulis, D; Frieri, M; Lark, G; Sansone, G; Schaefer, PA; Therattil, JM; Wang, SF; Zitt, M, 1998) |
" Patients who demonstrate improved asthma control with zileuton 600 mg QID may be able to reduce their daily dosage and/or frequency while still maintaining the same level of symptom control." | 2.68 | Randomized trial of zileuton in patients with moderate asthma: effect of reduced dosing frequency and amounts on pulmonary function and asthma symptoms. Zileuton Study Group. ( Dubé, LM; DuBuske, LM; Grossman, J; Lancaster, JF; Swanson, LJ, 1997) |
" dosing and an intravenous preparation for acute asthma exacerbations may enhance clinical utility and expand therapeutic indications." | 2.44 | Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease. ( Berger, W; Cairns, CB; De Chandt, MT, 2007) |
"The use of leukotriene inhibitors in treating atopic dermatitis, aspirin-intolerant asthma, and chronic idiopathic urticaria appears promising but has not been studied thoroughly." | 2.44 | Leukotriene inhibitors in the treatment of allergy and asthma. ( Dickerson, KS; Luttermoser, GK; Scow, DT, 2007) |
"As bronchial asthma is thought to be provoked by a variety of causes, therapeutic drug should be selected according to the state of the disease." | 2.39 | [5-lipoxygenase inhibitors in asthma therapy]. ( Tanaka, R, 1996) |
" Conversely, DO mice lacking adverse liver pathology following zileuton exposure experienced decreased hepatic concentrations of resistin and increased concentrations of insulin and leptin, providing potential clues into mechanisms of toxicity resistance." | 1.56 | Nitrosative Stress and Lipid Homeostasis as a Mechanism for Zileuton Hepatotoxicity and Resistance in Genetically Sensitive Mice. ( Bell, N; Gatti, DM; Harrill, AH; James, LP; Larson, GJ; Lyn-Cook, LE; Mattes, WB; Mayeux, PR; You, D, 2020) |
"Treatment with Zileuton for 2 weeks significantly increased thromboxane B(2) levels from baseline levels of 267 +/- 54 microg/l to 389 +/- 62 microg/l after 2 weeks of treatment (P < 0." | 1.32 | Zileuton, a 5-lipoxygenase inhibitor, increases production of thromboxane A2 and platelet aggregation in patients with asthma. ( Dev, A; Leong, AB; Wu, X, 2003) |
"Aspirin sensitivity was established previously in all six patients during a prior ASA oral challenge." | 1.31 | Lack of effect of the 5-lipoxygenase inhibitor zileuton in blocking oral aspirin challenges in aspirin-sensitive asthmatics. ( Daffern, PJ; Pauls, JD; Simon, RA; Stevenson, DD, 2000) |
" ABT-761 has shown excellent oral bioavailability and an extended duration of plasma levels in man, and initial results for a single 200 mg po dose have shown a significant protective effect against exercise- and adenosine-induced bronchoconstriction in asthmatics [215839]." | 1.31 | ABT-761 (Abbott). ( Reid, JJ, 2001) |
" Therefore, in this study, we determined if multiple dosing with zileuton, which theoretically could improve tissue levels, would provide protection against the antigen-induced EAR as well as the LAR." | 1.30 | The effects of multiple dosing with zileuton on antigen-induced responses in sheep. ( Abraham, WM; Allegra, L; Scuri, M, 1998) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (1.16) | 18.7374 |
1990's | 43 (50.00) | 18.2507 |
2000's | 32 (37.21) | 29.6817 |
2010's | 7 (8.14) | 24.3611 |
2020's | 3 (3.49) | 2.80 |
Authors | Studies |
---|---|
Chan, KH | 1 |
Stark, JM | 1 |
Mosquera, RA | 1 |
Brown, DL | 1 |
Menon, N | 1 |
Nguyen, TT | 1 |
Yadav, A | 1 |
Thalanayar Muthukrishnan, P | 1 |
Nouraie, M | 1 |
Parikh, A | 1 |
Holguin, F | 1 |
You, D | 1 |
Lyn-Cook, LE | 1 |
Gatti, DM | 1 |
Bell, N | 1 |
Mayeux, PR | 1 |
James, LP | 1 |
Mattes, WB | 1 |
Larson, GJ | 1 |
Harrill, AH | 1 |
Andersen, C | 1 |
Yadav, H | 1 |
Iyer, VN | 1 |
Dahlin, A | 2 |
Qiu, W | 1 |
Litonjua, AA | 1 |
Lima, JJ | 2 |
Tamari, M | 2 |
Kubo, M | 2 |
Irvin, CG | 2 |
Peters, SP | 2 |
Wu, AC | 1 |
Weiss, ST | 3 |
Tantisira, KG | 3 |
Seow, CY | 1 |
van Eeden, S | 1 |
Chen, WJ | 1 |
Liaw, SF | 1 |
Lin, CC | 1 |
Lin, MW | 1 |
Chang, FT | 1 |
Litonjua, A | 1 |
Eiymo Mwa Mpollo, MS | 1 |
Brandt, EB | 1 |
Shanmukhappa, SK | 1 |
Arumugam, PI | 1 |
Tiwari, S | 1 |
Loberg, A | 1 |
Pillis, D | 1 |
Rizvi, T | 1 |
Lindsey, M | 1 |
Jonck, B | 1 |
Carmeliet, P | 1 |
Kalra, VK | 1 |
Le Cras, TD | 1 |
Ratner, N | 1 |
Wills-Karp, M | 1 |
Hershey, GK | 1 |
Malik, P | 1 |
Lima, J | 1 |
Sylvia, J | 1 |
Klanderman, B | 1 |
Gelb, AF | 1 |
Taylor, CF | 1 |
Simmons, M | 1 |
Shinar, C | 1 |
Kroegel, C | 1 |
Valacer, DJ | 1 |
Wu, X | 1 |
Dev, A | 1 |
Leong, AB | 1 |
Jung, A | 1 |
Kemp, JP | 3 |
Snyder, L | 1 |
Blanc, PD | 1 |
Katz, PP | 1 |
Yelin, EH | 1 |
Eisner, MD | 1 |
Ziboh, VA | 1 |
Naguwa, S | 1 |
Vang, K | 1 |
Wineinger, J | 1 |
Morrissey, BM | 1 |
Watnik, M | 1 |
Gershwin, ME | 1 |
Leru, P | 1 |
Dahlén, SE | 2 |
Capra, V | 1 |
Thompson, MD | 1 |
Sala, A | 1 |
Cole, DE | 1 |
Folco, G | 1 |
Rovati, GE | 1 |
White, A | 1 |
Ludington, E | 1 |
Mehra, P | 1 |
Stevenson, DD | 2 |
Simon, RA | 2 |
Scow, DT | 1 |
Luttermoser, GK | 1 |
Dickerson, KS | 1 |
O'Connor, BJ | 1 |
Löfdahl, CG | 1 |
Balter, M | 1 |
Szczeklik, A | 2 |
Boulet, LP | 1 |
Cairns, CB | 2 |
Berger, W | 2 |
De Chandt, MT | 1 |
Wenzel, S | 3 |
Busse, W | 2 |
Calhoun, W | 1 |
Panettieri, R | 1 |
Peters-Golden, M | 1 |
Dube, L | 5 |
Walton-Bowen, K | 3 |
Russell, H | 1 |
Harris, J | 1 |
Nelson, H | 1 |
Kemp, J | 1 |
Corren, J | 1 |
Casale, T | 1 |
LaVallee, N | 1 |
Stepanians, M | 1 |
Watkins, PB | 1 |
Dube, LM | 7 |
Cameron, CM | 1 |
Kasten, LE | 1 |
Snapper, JR | 1 |
Brigham, KL | 1 |
Fischer, AR | 3 |
McFadden, CA | 1 |
Frantz, R | 1 |
Awni, WM | 1 |
Cohn, J | 6 |
Drazen, JM | 9 |
Israel, E | 7 |
Ado, VA | 1 |
Mokronosova, MA | 1 |
Perlamutrov, IuN | 1 |
Wenzel, SE | 3 |
Trudeau, JB | 1 |
Kaminsky, DA | 1 |
Martin, RJ | 1 |
Westcott, JY | 1 |
Ford-Hutchinson, AW | 1 |
Rosenberg, MA | 2 |
Lilly, CM | 2 |
Callery, JC | 2 |
Rubin, P | 5 |
White, MV | 1 |
Igarashi, Y | 1 |
Kaliner, MA | 1 |
Grossman, J | 2 |
Pierson, W | 1 |
Siegel, SC | 1 |
Tinkelman, D | 1 |
Murray, JJ | 1 |
Segal, AT | 1 |
Fish, J | 1 |
Kaiser, HB | 1 |
Ledford, D | 1 |
Rosenthal, R | 1 |
Lanni, C | 3 |
Pearlman, H | 1 |
Karahalios, P | 1 |
Shapiro, J | 1 |
Grimes, D | 1 |
Sturm, RJ | 1 |
Marinari, LR | 1 |
Carlson, RP | 1 |
Berkenkopf, JW | 1 |
Musser, JH | 1 |
Kreft, AF | 1 |
Weichman, BM | 1 |
McGill, KA | 2 |
Busse, WW | 2 |
Smith, LJ | 1 |
Liu, MC | 1 |
Lancaster, J | 1 |
Tanaka, R | 1 |
Larsen, JS | 1 |
Jackson, SK | 1 |
Van Schoor, J | 1 |
Joos, GF | 1 |
Kips, JC | 1 |
Drajesk, JF | 1 |
Carpentier, PJ | 2 |
Pauwels, RA | 1 |
Tan, RA | 2 |
Spector, SL | 2 |
Schwartz, HJ | 1 |
Petty, T | 1 |
Swanson, LJ | 3 |
Lancaster, JF | 3 |
Dekhuijzen, PN | 1 |
Bootsma, GP | 1 |
Wielders, PL | 1 |
van den Berg, LR | 1 |
Festen, J | 1 |
van Herwaarden, CL | 1 |
Dahlén, B | 1 |
Nizankowska, E | 1 |
Zetterström, O | 1 |
Bochenek, G | 1 |
Kumlin, M | 1 |
Mastalerz, L | 1 |
Pinis, G | 1 |
Boodhoo, TI | 1 |
Wright, S | 1 |
Horwitz, RJ | 1 |
Gómez, FP | 1 |
Iglesia, R | 1 |
Roca, J | 1 |
Barberà, JA | 1 |
Chung, KF | 1 |
Rodriguez-Roisin, R | 1 |
Drazen, J | 2 |
Santais, MC | 1 |
Callens, E | 1 |
Djebbar, R | 1 |
Ruff, F | 1 |
Frieri, M | 1 |
Therattil, JM | 1 |
Zitt, M | 1 |
Bouboulis, D | 1 |
Wang, SF | 1 |
Lark, G | 1 |
Schaefer, PA | 1 |
Sansone, G | 1 |
Lane, SJ | 1 |
Scuri, M | 1 |
Allegra, L | 1 |
Abraham, WM | 2 |
DuBuske, LM | 1 |
Lazarus, SC | 1 |
Lee, T | 1 |
Ochs, RF | 1 |
Yandava, CN | 1 |
Szczerback, N | 1 |
Hippensteel, R | 1 |
Pillari, A | 1 |
Schork, N | 1 |
Silverman, ES | 1 |
Katz, DA | 1 |
Drajesk, J | 1 |
Kupczyk, M | 1 |
Kuna, P | 1 |
Hasday, JD | 1 |
Meltzer, SS | 1 |
Moore, WC | 1 |
Wisniewski, P | 1 |
Hebel, JR | 1 |
Bleecker, ER | 1 |
Dellaripa, PF | 1 |
Wechsler, ME | 1 |
Roth, ME | 1 |
Lang, DM | 1 |
Pauls, JD | 1 |
Daffern, PJ | 1 |
Bisgaard, H | 1 |
Moy, ML | 1 |
Juniper, EF | 1 |
Krawiec, ME | 1 |
García-Marcos, L | 1 |
Schuster, A | 1 |
Rimbrot, S | 1 |
Bennett, M | 1 |
Komorovski, M | 1 |
Levy, Y | 1 |
Reid, JJ | 1 |
Minoguchi, K | 1 |
Adachi, M | 1 |
Hayden, ML | 1 |
Ahmed, A | 1 |
Cortes, A | 1 |
Sielczak, MW | 1 |
Hinz, W | 1 |
Bouska, J | 1 |
Bell, RL | 1 |
O'Donnell, M | 1 |
Payne, AN | 2 |
Jackson, WP | 1 |
Salmon, JA | 1 |
Nicholls, A | 1 |
Yeadon, M | 1 |
Garland, LG | 1 |
Hui, KP | 1 |
Taylor, IK | 1 |
Taylor, GW | 1 |
Kesterson, J | 1 |
Barnes, NC | 1 |
Barnes, PJ | 1 |
Bukantz, SC | 1 |
Raub, W | 1 |
Dermarkarian, R | 1 |
Rosenberg, M | 1 |
Sperling, R | 1 |
Taylor, G | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Evaluation of Additive Effects of Zileuton to Advair on Total Exhaled, Bronchial, and Alveolar Nitric Oxide in Asthmatics[NCT00575861] | Phase 4 | 19 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
[NCT00005564] | 0 participants | Observational | 1997-07-31 | Completed | |||
Fractional Concentration of Exhaled NO(FeNO) to Direct The Treatment of Sub-acute Cough:A Prospective, Open Label, Randomized and Placebo-Controlled Trial[NCT02655562] | Phase 4 | 200 participants (Anticipated) | Interventional | 2016-04-30 | Suspended (stopped due to There are difficulties in recruiting patients) | ||
Predicting the Bronchoprotective Response to a Leukotriene Modifier by Genetic Polymorphism[NCT00116324] | Phase 3 | 150 participants | Interventional | 2003-04-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
30 reviews available for hydroxyurea and Asthma
Article | Year |
---|---|
[What helps for persistent symptoms of asthma during inhalative steroid therapy?].
Topics: Acetates; Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; | 2011 |
New treatments for asthma: the role of leukotriene modifier agents.
Topics: Acetates; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Asthma, Exercise-I | 1999 |
[Anti-leukotrienes in allergic diseases in children].
Topics: Acetates; Asthma; Child; Cyclopropanes; Humans; Hydroxyurea; Leukotriene Antagonists; Leukotrienes; | 2003 |
Recent advances in the management of asthma using leukotriene modifiers.
Topics: Acetates; Administration, Inhalation; Adolescent; Adult; Asthma; Child; Child, Preschool; Chromones; | 2003 |
Leukotrienes antagonists in the management of bronchial asthma.
Topics: Asthma; Humans; Hydroxyurea; Leukotriene Antagonists; Leukotrienes | 2003 |
Treatment of asthma with antileukotrienes: first line or last resort therapy?
Topics: Acetates; Animals; Asthma; Clinical Trials as Topic; Cyclopropanes; Humans; Hydroxyurea; Leukotriene | 2006 |
Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends.
Topics: Adult; Animals; Asthma; Cardiovascular Diseases; Child; Child, Preschool; Dermatitis, Atopic; Female | 2007 |
Leukotriene inhibitors in the treatment of allergy and asthma.
Topics: Acetates; Anti-Asthmatic Agents; Asthma; Asthma, Exercise-Induced; Cyclopropanes; Dermatitis, Atopic | 2007 |
Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Asthma; Dermatitis, Atopic; Drug Administration Schedule; H | 2007 |
Inflammation and airway reactivity.
Topics: Aerosols; Animals; Asthma; Disease Models, Animal; Dogs; Endotoxins; Granulocytes; Guinea Pigs; Hist | 1984 |
[Allergy and leukotrienes].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 5-Lipoxygenase; Arachidonic Acid; Asthma; Derm | 1995 |
Leukotriene antagonists and inhibitors: clinical applications.
Topics: Animals; Asthma; Glomerulonephritis; Humans; Hydroxyurea; Indoles; Inflammatory Bowel Diseases; Leuk | 1995 |
Zileuton.
Topics: Arthritis, Rheumatoid; Asthma; Humans; Hydroxyurea; Lipoxygenase Inhibitors | 1996 |
Leukotrienes in asthma. The potential therapeutic role of antileukotriene agents.
Topics: Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Humans; Hydroxyurea | 1996 |
[5-lipoxygenase inhibitors in asthma therapy].
Topics: Arachidonate 5-Lipoxygenase; Arachidonic Acids; Asthma; Humans; Hydroxyurea; Lipoxygenase Inhibitors | 1996 |
Antileukotriene therapy for asthma.
Topics: Asthma; Humans; Hydroxyurea; Inflammation; Leukotrienes; Lipoxygenase Inhibitors | 1996 |
Antileukotriene agents.
Topics: Anti-Asthmatic Agents; Asthma; Humans; Hydroxyurea; Indoles; Leukotriene Antagonists; Leukotrienes; | 1997 |
New directions in asthma drug therapy.
Topics: Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Chromones; Humans; Hydroxyur | 1998 |
The role of antileukotrienes in asthma management.
Topics: Acetates; Animals; Anti-Asthmatic Agents; Asthma; Chromones; Cyclopropanes; Humans; Hydroxyurea; Ind | 1998 |
New approaches to anti-inflammatory therapy for asthma.
Topics: Anti-Asthmatic Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Di | 1998 |
The role of leukotriene modifiers in the treatment of asthma.
Topics: Animals; Asthma; Humans; Hydroxyurea; Indoles; Leukotriene Antagonists; Leukotrienes; Lipoxygenase I | 1998 |
Clinical pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors.
Topics: Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Humans; Hydroxyurea; Indoles | 1998 |
[Potential importance of antileukotrienes in the treatment of asthma and other inflammatory diseases: apropos of a new pharmacological class].
Topics: Acetophenones; Adult; Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthr | 1998 |
Leukotriene antagonism in asthma and rhinitis.
Topics: Acetates; Asthma; Bronchi; Cyclopropanes; Humans; Hydroxyurea; Indoles; Leukotriene Antagonists; Leu | 1998 |
[The role of leukotrienes in inflammation and leukotriene inhibitors].
Topics: Acetates; Arachidonate 5-Lipoxygenase; Asthma; Cyclopropanes; Humans; Hydroxyurea; Indoles; Leukotri | 1999 |
Leukotriene modifiers in pediatric asthma management.
Topics: Acetates; Adrenal Cortex Hormones; Anti-Asthmatic Agents; Asthma; Child; Cyclopropanes; Humans; Hydr | 2001 |
Leukotriene inhibitors and non-steroidal therapies in the treatment of asthma.
Topics: Acetates; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Asthma; Bronchocon | 2001 |
Antileukotrienes in asthma: present situation.
Topics: Acetates; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Chromones; Clinical Trials as Topic; | 2001 |
[Leukotriene modifiers].
Topics: Acetates; Asthma; Chromones; Cyclopropanes; Humans; Hydroxyurea; Indoles; Leukotriene Antagonists; L | 2001 |
Leukotriene modifiers. Expanded role may be on horizon.
Topics: Acetates; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma; Cyclopropanes; Drug Interactions; | 2000 |
27 trials available for hydroxyurea and Asthma
Article | Year |
---|---|
Genome-wide association study of leukotriene modifier response in asthma.
Topics: Acetates; Anti-Asthmatic Agents; Asthma; Cohort Studies; Cyclopropanes; Gene-Environment Interaction | 2016 |
5-lipoxygenase pharmacogenetics in asthma: overlap with Cys-leukotriene receptor antagonist loci.
Topics: Acetates; Adult; Anti-Asthmatic Agents; Asthma; Cyclopropanes; Cysteine; Female; Forced Expiratory V | 2009 |
Role of add-on zileuton on total exhaled, large airway, and small airway/alveolar nitric oxide in moderate-severe persistent adult asthmatics on fluticasone 250 microg/Salmeterol 50 microg.
Topics: Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; As | 2009 |
Suppression of leukotriene B4 generation by ex-vivo neutrophils isolated from asthma patients on dietary supplementation with gammalinolenic acid-containing borage oil: possible implication in asthma.
Topics: Adult; Aged; Arthritis, Rheumatoid; Asthma; Dietary Supplements; Double-Blind Method; Fatty Acids; F | 2004 |
Effect of leukotriene modifier drugs on the safety of oral aspirin challenges.
Topics: Acetates; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Anti-Asthmatic Agents; Aspirin; Asthma; | 2006 |
Zileuton added to low-dose inhaled beclomethasone for the treatment of moderate to severe persistent asthma.
Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Bec | 2007 |
The safety and efficacy of zileuton controlled-release tablets as adjunctive therapy to usual care in the treatment of moderate persistent asthma: a 6-month randomized controlled study.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Asthma; Child; Delayed-Action | 2007 |
Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: a 3-month randomized controlled study.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non- | 2007 |
Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Asthma; Chemical and Drug Induced Liver In | 2007 |
Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects.
Topics: Adult; Arachidonate 5-Lipoxygenase; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; | 1995 |
Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma.
Topics: Adolescent; Adult; Asthma; Bronchial Provocation Tests; Bronchoalveolar Lavage Fluid; Bronchoconstri | 1995 |
Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma.
Topics: Adult; Aspirin; Asthma; Blood Proteins; Chymases; Cross-Over Studies; Double-Blind Method; Eosinophi | 1994 |
The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma.
Topics: Adult; Albuterol; Asthma; Double-Blind Method; Drug Therapy, Combination; Female; Forced Expiratory | 1993 |
The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin.
Topics: Adult; Arachidonate 5-Lipoxygenase; Aspirin; Asthma; Bronchoconstriction; Double-Blind Method; Drug | 1993 |
Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group.
Topics: Adrenergic beta-Agonists; Adult; Analysis of Variance; Asthma; Double-Blind Method; Drug Administrat | 1996 |
Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Anti-Asthmatic Agents; Asthma; Bronchoconstriction; Dou | 1996 |
The effect of ABT-761, a novel 5-lipoxygenase inhibitor, on exercise- and adenosine-induced bronchoconstriction in asthmatic subjects.
Topics: Adenosine; Adult; Asthma; Bronchi; Bronchial Provocation Tests; Bronchoconstriction; Cross-Over Stud | 1997 |
A randomized controlled trial comparing zileuton with theophylline in moderate asthma. The Zileuton Study Group.
Topics: Adult; Asthma; Bronchodilator Agents; Double-Blind Method; Female; Forced Expiratory Volume; Humans; | 1998 |
Effects of single-dose zileuton on bronchial hyperresponsiveness in asthmatic patients treated with inhaled corticosteroids.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Asthma; Bronchial Hyperreactivity; Bronc | 1997 |
Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics.
Topics: Adrenergic beta-Agonists; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Bronchial Hyperr | 1998 |
The effects of 5-lipoxygenase inhibition by zileuton on platelet-activating-factor-induced pulmonary abnormalities in mild asthma.
Topics: Adult; Airway Resistance; Asthma; Cross-Over Studies; Double-Blind Method; Female; Humans; Hydroxyur | 1998 |
Randomized trial of zileuton in patients with moderate asthma: effect of reduced dosing frequency and amounts on pulmonary function and asthma symptoms. Zileuton Study Group.
Topics: Adolescent; Adult; Aged; Asthma; Double-Blind Method; Drug Administration Schedule; Humans; Hydroxyu | 1997 |
Safety and clinical efficacy of zileuton in patients with chronic asthma.
Topics: Asthma; Chronic Disease; Disease Management; Forced Expiratory Volume; Humans; Hydroxyurea; Lipoxyge | 1998 |
Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment.
Topics: Alleles; Anti-Asthmatic Agents; Arachidonate 5-Lipoxygenase; Asthma; Gene Frequency; Genetic Variati | 1999 |
Anti-inflammatory effects of zileuton in a subpopulation of allergic asthmatics.
Topics: Adult; Asthma; Bronchial Provocation Tests; Bronchoalveolar Lavage Fluid; Cytokines; Double-Blind Me | 2000 |
Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients.
Topics: Adult; Allergens; Asthma; Double-Blind Method; Forced Expiratory Volume; Humans; Hydroxyurea; Leukot | 1991 |
The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air.
Topics: Asthma; Bronchial Provocation Tests; Bronchoconstriction; Calcimycin; Cold Temperature; Double-Blind | 1990 |
29 other studies available for hydroxyurea and Asthma
Article | Year |
---|---|
Screening for asthma in preschool children with sickle cell disease.
Topics: Aged; Anemia, Sickle Cell; Asthma; Child, Preschool; Dermatitis, Atopic; Humans; Hydroxyurea; Prospe | 2023 |
Zileuton use and phenotypic features in asthma.
Topics: Adult; Aged; Anti-Asthmatic Agents; Asthma; Female; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Lu | 2020 |
Nitrosative Stress and Lipid Homeostasis as a Mechanism for Zileuton Hepatotoxicity and Resistance in Genetically Sensitive Mice.
Topics: Animals; Anti-Asthmatic Agents; Asthma; Chemical and Drug Induced Liver Injury; Collaborative Cross | 2020 |
38-Year-Old Man With Asthma and Eosinophilia.
Topics: Adult; Anti-Asthmatic Agents; Antineoplastic Agents; Asthma; Diagnosis, Differential; Disease Progre | 2017 |
The phosphatidylinositide 3-kinase (PI3K) signaling pathway is a determinant of zileuton response in adults with asthma.
Topics: Asthma; Cell Line; Humans; Hydroxyurea; Leukotrienes; Phosphatidylinositol 3-Kinases; Polymorphism, | 2018 |
Airway remodeling in asthma: tumor of the airway?
Topics: Airway Remodeling; Allergens; Animals; Asthma; Hydroxyurea; Leukotriene Antagonists; Lung; Male | 2013 |
Effects of zileuton on airway smooth muscle remodeling after repeated allergen challenge in brown Norway rats.
Topics: Airway Remodeling; Allergens; Animals; Asthma; Bronchoalveolar Lavage Fluid; Drug Evaluation, Precli | 2013 |
Placenta growth factor augments airway hyperresponsiveness via leukotrienes and IL-13.
Topics: Anemia, Sickle Cell; Animals; Asthma; Disease Models, Animal; Hydroxyurea; Interleukin-13; Leukotrie | 2016 |
Zileuton, a 5-lipoxygenase inhibitor, increases production of thromboxane A2 and platelet aggregation in patients with asthma.
Topics: Adult; Aged; Asthma; Female; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Male; Middle Aged; Platel | 2003 |
Leukotriene modifier use and asthma severity: how is a new medication being used by adults with asthma?
Topics: Acetates; Adult; Anti-Asthmatic Agents; Asthma; Cyclopropanes; Female; Health Status Indicators; Hos | 2004 |
WY-50,295 tromethamine, a novel, orally active 5-lipoxygenase inhibitor: biochemical characterization and antiallergic activity.
Topics: Administration, Oral; Animals; Arachidonate 5-Lipoxygenase; Arachidonic Acid; Asthma; Female; Guinea | 1993 |
Zileuton for asthma.
Topics: Adolescent; Adult; Asthma; Child; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Dr | 1997 |
Allergen-stimulated leukotriene B4 and interleukin-8 levels in patients with asthma and allergic rhinitis-modulation by a lipid pathway inhibitor.
Topics: Adult; Aged; Allergens; Asthma; Female; Humans; Hydroxyurea; Interleukin-8; Leukocytes, Mononuclear; | 1998 |
Drugs for asthma.
Topics: Acetates; Administration, Inhalation; Administration, Oral; Adolescent; Adrenal Cortex Hormones; Adr | 1999 |
The effects of multiple dosing with zileuton on antigen-induced responses in sheep.
Topics: Airway Resistance; Animals; Asthma; Bronchial Provocation Tests; Disease Models, Animal; Drug Admini | 1998 |
Drugs for asthma.
Topics: Acetates; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adrenergic beta | 2000 |
The use of newer asthma and allergy medications during pregnancy. The American College of Obstetricians and Gynecologists (ACOG) and The American College of Allergy, Asthma and Immunology (ACAAI).
Topics: Abnormalities, Drug-Induced; Acetates; Administration, Inhalation; Administration, Intranasal; Admin | 2000 |
Recurrent panniculitis in a man with asthma receiving treatment with leukotriene-modifying agents.
Topics: Acetates; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Cyclopropanes; Dia | 2000 |
Antileukotriene agents and aspirin-sensitive asthma: are we removing the second bassoonist or skating to where the puck is gonna be?
Topics: Aspirin; Asthma; Bronchial Spasm; Humans; Hydroxyurea; Leukotriene Antagonists; Therapeutic Equivale | 2000 |
Lack of effect of the 5-lipoxygenase inhibitor zileuton in blocking oral aspirin challenges in aspirin-sensitive asthmatics.
Topics: Administration, Oral; Aspirin; Asthma; Desensitization, Immunologic; Humans; Hydroxyurea; Leukotrien | 2000 |
Clinical predictors of health-related quality of life depend on asthma severity.
Topics: Adult; Albuterol; Analysis of Variance; Asthma; Female; Follow-Up Studies; Humans; Hydroxyurea; Male | 2001 |
[Eosinophilic ascites as a presenting symptom of the hypereosinophilic syndrome].
Topics: Adult; Ascitic Fluid; Asthma; Diagnosis, Differential; Eosinophilia; Humans; Hydroxyurea; Hypereosin | 2001 |
Safety of antileukotriene agents in asthma management.
Topics: Acetates; Asthma; Churg-Strauss Syndrome; Clinical Trials as Topic; Cyclopropanes; Humans; Hydroxyur | 2001 |
ABT-761 (Abbott).
Topics: Asthma; Clinical Trials, Phase III as Topic; Humans; Hydroxyurea; Lipoxygenase Inhibitors | 2001 |
The 5-lipoxygenase inhibitor zileuton blocks antigen-induced late airway responses, inflammation and airway hyperresponsiveness in allergic sheep.
Topics: Administration, Oral; Animals; Antigens; Asthma; Bronchial Hyperreactivity; Bronchoalveolar Lavage F | 1992 |
Therapeutic approaches to reduce airway inflammation.
Topics: Animals; Anti-Inflammatory Agents; Asthma; Blood Platelets; Bronchi; Cell Adhesion Molecules; Humans | 1991 |
Hydroxamic acids and hydroxyureas as novel, selective 5-lipoxygenase inhibitors for possible use in asthma.
Topics: Anaphylaxis; Animals; Asthma; Benzeneacetamides; Bronchial Diseases; Guinea Pigs; Humans; Hydroxamic | 1991 |
Asthma: the molecular light at the end of the tracheal tunnel.
Topics: Asthma; Humans; Hydroxyeicosatetraenoic Acids; Hydroxyurea; Leukotrienes; Lipoxygenase Inhibitors; P | 1991 |
From the National Institutes of Health.
Topics: Arthritis, Juvenile; Asthma; CD4 Antigens; Cells, Cultured; Exotoxins; HIV-1; HLA Antigens; Humans; | 1991 |